Viresolve barrier filters are a key component of Merck's viral safety assurance programme to mitigate the risk of viral contamination in upstream bioprocesses and minimise the potential impact on drug supply and patient safety.
The viral safety assurance programme takes a holistic approach to viral safety, offering solutions to prevent viruses from entering upstream processes, detect viruses in cells, raw materials and process intermediates and remove viruses in downstream processes.
“Viral contamination is a constant process threat,” said Andrew Bulpin, Head of the Process Solutions business, Life Science, at Merck.
“One viral particle has the potential to initiate a bioreactor contamination. Our new Viresolve barrier filters reduce the risk of bioreactor contaminations that cause process downtime, costly investigations and possible drug supply disruptions that could impact patients.”
Scalable from bench through commercial manufacturing, Viresolve barrier filters offer high flux and high capacity virus filtration to ensure productivity, without impacting cell culture performance or protein quality attributes.
Available now in sizes up to one square meter, including scalable micro filters for process development, these capsule filters are easy to implement directly in front of the bioreactor or into a media storage container.
The Viresolve barrier filter is the latest addition to the Viresolve portfolio, now offering solutions for virus filtration in both upstream and downstream applications.
The Process Solutions business area of the Life Science business sector of Merck provides the industry’s most comprehensive portfolio of high quality products and services for biopharmaceutical manufacturing.
